October 31st, 2013
EUROMAX Meets Primary Endpoint But Editorialist Raises Questions
Larry Husten, PHD
When started during transport to the hospital during a heart attack, bivalirudin (Angiox, Medicines Company) improves clinical outcomes and reduces major bleeding, though at the cost of a small but significant risk in stent thrombosis. The results of the European Ambulance Acute Coronary Syndrome (ACS) Angiography) Trial (EUROMAX) were presented on Wednesday by Phillippe Gabriel […]
NEJM Journal Watch — Recent Cardiology Articles- Atrial Fibrillation and Stable Coronary Artery Disease — What Is the Optimal Anticoagulation–Antiplatelet Regimen?
- β-Blockers After Myocardial Infarction
- Updated Guideline for Perioperative Cardiovascular Management of Patients Undergoing Noncardiac Surgery
- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?